The SARS-CoV-2 Conserved Macrodomain Is a Mono-ADP-Ribosylhydrolase

Abstract

SARS-CoV-2 has recently emerged into the human population and has led to a worldwide pandemic of COVID-19 that has caused more than 1.2 million deaths worldwide. With no currently approved treatments, novel therapeutic strategies are desperately needed.

Cited by papers we hold 3

• Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 macrodomain of SARS-CoV-2 · 2023
  No notice
• In silico analysis of SARS-CoV-2 proteins as targets for clinically available drugs · 2022
  Not checked
• Structural biology of SARS-CoV-2: open the door for novel therapies · 2022
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.